LÖSEMİ PATOGENEZİNDE miRNA 15A/16–1 LOKUS DELESYONLARININ VE PROTEİN L-İZOASPARTAT O-METİLTRANSFERAZ (PCMT1) ENZİMİNİN ROLÜ

Kanser, ülkemizde ve dünyada sıklıkla görülen hastalıklardan birisidir. Karsinojenez sırasında büyük değişimlere uğrayan hücresel gen ifadesi profili DNA dizisi dışında DNA metilasyonu, kodlanmayan RNA’lar (ncRNA), RNA interferansı (RNAi), histon varyantları ve post-translasyonel histon modifikasyonları gibi başkaca epigenetik mekanizmalar tarafından da kontrol edilebilmektedir. Bununla birlikte; mutasyonlar,delesyonlar ve translokasyonlar gibi çeşitli sebepler sonucu ortaya çıkan genetik anomaliler kanser oluşumunda ve tedaviye verilen yanıtta önemli rol oynamakta ve klinikte, kanser alt tiplerinin belirlenmesinde incelenmektedir. 13. kromozomun q kolunda bulunan miRNA 15a/16-1 lokusu delesyonlarının Mcl1, Bcl2, Ets1, Jun gibi kanser ile ilişkili birçok geni etkilediği gösterilmiştir. Ayrıca, bu miRNA’ların regüle ettiği Protein L-isoaspartate O-methyltransferase (PCMT1) proteinin apoptoz yolağı üzerindeki etkisi dolayısıyla karsinojenez üzerinde önemli rol oynadığı birçok çalışma ile vurgulanmıştır. Literatürde miRNA 15a/16-1 lokusu ve p53 arasında hücre proliferasyonu ve büyümesini sağlayan sinyallerin üretimini düzenleyen birfeedback döngüsünün varlığı tartışılmaktadır. Yapılan çalışmalar, miRNA 15a/16-1 lokusunu tümör baskılayıcı gen bölgesi, PCMT1’i ise onkogen olarak tanımlamaktadır. Buna paralel olarak, miRNA 15a/16-1 lokusunu da içeren 13q14.3 bölgesi delesyonu birçok lenfoid ve miyeloid lösemi alt türlerinde tespit edilmişolup, klinikte rutin taramalara dahil edilme potansiyeline sahiptir. Lösemi hastalarında 13q14.3 bölgesi delesyonunun araştırılması hastalığın alt tiplerinin sınıflandırılmasını ve hatta uygulanacak tedavi rejimini yönlendirebilecek önemli sonuçlar elde edilmesini sağlayabilecektir.

A NEW PERSPECTIVE ON CARCINOGENESIS: miRNA 15A/16–1 CLUSTER DELETIONS PROMOTE CELL SURVIVAL VIA PROTEIN L-ISOASPARTATE O-METHYLTRANSFERASE (PCMT1) ACTIVITY

Cancer is a commonly encountered disease both in Turkey and worldwide. Cellular gene expression profiles that drastically change during carcinogenesis can be regulated via several epigenetic mechanisms such as DNA methylation, non-coding RNAs (ncRNA), RNA interference (RNAi), histone variants and post-translational modifications of histones. In addition to these mechanisms, genetic anomalies that arise due to various reasons including mutations, deletions and translocations have significant roles both in carcinogenesis and the response to treatment and are screened routinely in clinic when determining cancer subtypes. miRNA 15a/16-1 cluster which is located on the q arm of chromosome 13 is often deleted in cancers and regulates the activity of several cancer-associated genes such as Mcl1, Bcl2, Ets1, Jun. Furthermore, the role of Protein L-isoaspartate O-methyltransferase (PCMT1) which is regulated bythese miRNAs, in carcinogenesis through its effects in apoptosis pathway is emphasized by various studies. It is suggested that there is a feedback loop between miRNA 15a/16-1 cluster and p53 which regulates cellular signals for proliferation and cell survival. Studies describe miRNA 15a/16-1 cluster as a tumor suppressor, while identifying PCMT1 as an oncogene. In line with this, deletions in the 13q14.3 region which also spans the miRNA 15a/16-1 cluster are detected in multiple lymphoid and myeloid leukemia subtypes and have the potential to be included in routine clinical genetic screens. Examining 13q14.3 deletions in leukemia patients has the potential to yield important results that could be useful both in determining cancer subtypes and deciding which therapeutic regime to apply on a single-patient basis.

PDF

___

1. Huisinga KL, Brower-Toland B & Elgin SC. The contradictory definitions of heterochromatin: transcription and silencing. Chromosoma 2006:115, 110–122.
2. Cam HP, Sugiyama T, Chen ES, Chen X, FitzGerald PC, Grewal SI. Comprehensive analysis of heterochromatin- and RNAi-mediated epigenetic control of the fission yeast genome. Nat Genet. 2005:37(8):809-19
3. Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol. 2004:16(3):223-9
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857–866.
5. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;26;99(24):15524-9.
6. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008; 105(13):5166-71.
7. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010; 17(2):215-20.
8. Kim JA, Hwang B, Park SN, Huh S, Im K, Choi S, Chung HY, Huh J, Seo EJ, Lee JH, Bang D, Lee DS. Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PLoS One. 2016 Dec 13;11(12):e0167641.
9. Bagir EK, Acikalin A, Alsancak P, Paydas S, Gurkan E, Ergin M. Prevalence of cytogenetic abnormalities in chronic lymphocytic leukemia in the southern part of Turkey. Indian J Cancer. 2017 Jul-Sep;54(3):572-575.
10. Tagawa H, Ikeda S, Sawada K. Role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci. 2013 Jul;104(7):801-9.
11. Wada M, Okamura T, Okada M, Teramura M, Masuda M, Motoji T, Mizoguchi H. Frequent chromosome arm 13q deletion in aggressive non-Hodgkin’s lymphoma. Leukemia 1999; 13:792–798.
12. Lens D, Matutes E, Catovsky D, Coignet LJ. Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 2000; 14: 427–430.
13. Königsberg R1, Ackermann J, Kaufmann H, Zojer N, Urbauer E, Krömer E, Jäger U, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia. 2000 Nov;14(11):1975-9.
14. Cave H, Avet-Loiseau H, Devaux I, Rondeau G, Boutard P, Lebrun E, Mechinaud F, Vilmer E, Grandchamp B. Deletion of chromosomal region 13q14.3 in childhood acute lymphoblastic leukemia. Leukemia 2001; 15: 371–376.
15. Rowntree C, Duke V, Panayiotidis P, Kotsi P, Palmisano GL, Hoffbrand AV, Foroni L. Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia. Leukemia 2002; 16(7):1267-75.
16. Mertens D, Wolf S, Schroeter P, Schaffner C, Döhner H, Stilgenbauer S, Lichter P. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood. 2002 Jun 1;99(11):4116-21.
17. Lovat F, Fassan M, Gasparini P, Rizzotto L, Cascione L, Pizzi M, Vicentini C, Balatti V, Palmieri D, Costinean S, Croce CM. miR-15b/16-2 deletion promotes B-cell malignancies. Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11636-41.
18. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001 Apr 1;61(7):2870-7.
19. Humplikova L, Kollinerova S, Papajik T, Pikalova Z, Holzerova M, Prochazka V, Divoka M, Modriansky M, Indrak K, Jarosova M. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Dec;157(4):284-93.
20. Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR15a/16-1 expression. Leukemia. 2017 Nov;31(11):2336-2346.
21. Zhang L, Zhou L, Shi M, Kuang Y, Fang L. Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression. Oncol Lett. 2018 Jan;15(1):1287-1296.
22. Marengo B, Monti P, Miele M, Menichini P, Ottaggio L, Foggetti G, Pulliero A, Izzotti A, Speciale A, Garbarino O, Traverso N, Fronza G, Domenicotti C. Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation. Sci Rep. 2018 Sep 13;8(1):13762.
23. Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003 Feb 15;101(4):1220-35.
24. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9.
25. Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Bcl-2 level as a biomarker for 13q14 deletion in CLL. Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):237-47.
26. Yang T, Thakur A, Chen T, Yang L, Lei G, Liang Y, Zhang S, Ren H, Chen M. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 2015 Jun; 36(6):4357-65.
27. Lu W, Feng L, Zhang Y, Ma Y, Li P, Wang Y, Du Y, Chen X, Wu S, Zhao G, Lou W. miR-15a induces cell apoptosis by targeting BCL2L2 and BCL2 in HPV-positive hypopharyngeal squamous cell carcinoma. Oncol Rep. 2016 Oct; 36(4):2169-76.
28. Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu JC, Zheng F, Liu SM, Han L, Zhang JK, Luo XY, Zhou X. MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-γ. Asian Pac J Cancer Prev. 2014; 15(16):6949-54.
29. Liu R, Lu Z, Gu J, Liu J, Huang E, Liu X, Wang L, Yang J, Deng Y, Qian J, Luo F, Wang Z, Zhang H, Jiang X, Zhang D, Qian J, Liu G, Zhu H, Qian Y, Liu Z, Chu Y. MicroRNAs 15A and 16-1 activate signaling pathways that mediate chemotaxis of immune regulatory B cells to colorectal tumors. Gastroenterology. 2018 Feb;154(3):637-651.e7.
30. Ogawara M, Takahashi M, Shimizu T, Nakajima M, Setoguchi Y, Shirasawa T. Adenoviral Expression of Protein L-isoaspartyl Methyltransferase (PIMT) Partially Attenuates the Biochemical Changes in PIMT-deficient Mice. Journal of Neuroscience Research 2002; 69, 353-361.
31. Biterge B. Protein L-Isoaspartate O-Methyltransferase (PCMT1): A Key Player of Spontaneously Arisen Protein Damage Repair. Anatomy Physiol Biochem Int J. 2017; 3(1): 555605.
32. Lee JC, Kang SU, Jeon Y, Park JW, You JS, Ha SW, Bae N, Lubec G, Kwon SH, Lee JS, Cho EJ, Han JW. Protein L-isoaspartyl Methyltransferase Regulates p53 Activity. Nature Communications, 2011; 3:927.
33. Cimmino A, Capasso R, Muller F, Sambri I, Masella L, Raimo M, De Bonis ML, D’Angelo S, Zappia V, Galletti P, Ingrosso D. Protein isoaspartate methyltransferase prevents apoptosis induced by oxidative stress in endothelial cells: role of Bcl-Xl deamidation and methylation. PLoS One 2008; 3(9):e3258.
34. Young AL, Carter WG, Doyle HA, Mamula MJ, Aswad DW. Structural Integrity of Histone H2B in vivo Requires the Activity of Protein L-isoaspartate O methyltransferase, a Putative Protein Repair Enzyme. The Journal of Biological Chemistry 2001; 276, 37161-37165.
35. Young GW, Hoofring SA, Mamula MJ, Doyle HA, Bunick GJ, Hu Y, Aswad DW. Protein L-isoaspartyl Methyltransferase Catalyzes in vivo Racemization of Aspartate- 25 in Mammalian Histone H2B. The Journal of Biological Chemistry 2005; 280, 26094-26098.
36. Carter WG, Aswad DW. Formation, Localization and Repair of L-isoaspatyl Sites in Histones H2A and H2B in Nucleosomes from Rat Liver and Chicken Erythrocytes. Biochemistry 2008;47, 10757-10764.
37. Biterge B, Richter F, Mittler G, Schneider R. Methylation of histone H4 at aspartate 24 by Protein L-isoaspartate O-methyltransferase (PCMT1) links histone modifications with protein homeostasis. Nature Scientific Reports 2014; 4:6674.
38. Sambri I, Capasso R, Pucci P, Perna AF, Ingrosso D. The microRNA 15a/16-1 cluster down-regulates protein repair isoaspartyl methyltransferase in hepatoma cells: implications for apoptosis regulation. J Biol Chem. 2011; 286(51):43690-700.
39. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P. Loss of p53 and altered miR15-a/16-1-MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia. 2014 Jan;28(1):118-28.
40. Dong L, Li Y, Xue D, Liu Y. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer. IUBMB Life, 2018; 70(4):291-299.
41. Huang E, Liu R, Chu Y. miRNA-15a/16: as tumor suppressors and more. Future Oncol. 2015;11(16):2351-63.
42. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 5;305(1):59-67.
43. Alderman C, Yang Y. The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p. RNA Dis. 2016;3(4). pii: e1450.
44. Tian X, Zhang J, Yan L, Dong JM, Guo Q. MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6442-9.
45. Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, Hose D, Ho AD, Goldschmidt H, Neben K. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011 May 15;117(10):2136-44. doi: 10.1002/cncr.25775.
46. Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013 Mar;31(1):41-8.
47. Meyer S, Eden T, Kalirai H. Dexamethasone protects against Cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells. Cancer Biol Ther. 2006;5(8):915-20.
48. Lin KT, Wang LH. New dimension of glucocorticoids in cancer treatment. Steroids 2016;111:84-88.
49. Fietz ER, Keenan CR, López-Campos G, Tu Y, Johnstone CN, Harris T, Stewart AG. Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. Sci Rep. 2017:6;7:43774.
50. Schlossmacher G, Stevens A, White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol. 2011;211(1):17-25.